Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …

In order to properly understand the spread of SARS-CoV-2 infection and development of
humoral immunity, researchers have evaluated the presence of serum antibodies of people …

SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has
resulted in millions of deaths worldwide. Novel coronavirus infections in humans have …

Several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …

Summary The World Health Organization has declared the ongoing outbreak of COVID-19,
which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack …

SARS-CoV-2 variants of concern (VOCs) have emerged worldwide, with implications on the
spread of the pandemic. Characterizing the cross-reactivity of antibodies against these …

Preexisting immunity against seasonal coronaviruses (CoVs) represents an important
variable in predicting antibody responses and disease severity to severe acute respiratory …

Preexisting antibodies to endemic coronaviruses (CoV) that cross-react with SARS-CoV-2
have the potential to influence the antibody response to COVID-19 vaccination and infection …

Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual
characteristics influencing it, including the impact of pre-existing antibodies to human …

Background Antibodies raised against human seasonal coronaviruses (sCoVs), which are
responsible for the common cold, are known to cross-react with SARS-CoV-2 antigens. This …